Novartis has made radiopharma one of the pillars of its business, adding Lutathera through the AAA acquisition and Pluvicto via its $2.1 billion purchase of Endocyte in 2019, whilst growing its ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

One study conducted in Thailand compared the effectiveness of PILs to traditional package inserts (PIs) in enhancing patients' medication safety knowledge. The findings revealed that patients who ...

1 Lutetium 177 vipivotide tetraxetan (PLUVICTO®) for prostate-specific membrane antigen (PSMA)-positive mCRPC patients who had previously been treated with an ARPI and taxane-based chemotherapy In ...

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...